

F228

XP-002477850

C:\EPOPROGS\SEA\1\1\epodata\sealeplog\internal.log

WPI / Thomson

AN - 2002-523513 [56]
AP - JP20010277501 20010913
CN - RA0JI5-K RA0JI5-M R00184-K R00184-M R10162-K R10162-M R04370-K
R04370-M R10620-K R10620-M R03838-K R03838-M R00048-K R00048-M
R14840-K R14840-M R11928-K R11928-M R14940-K R14940-M R16287-K R16287-M
CPY - TAIS
DC - B05
DCR - [1] 108672 CL; 103865 CL; 101656 CL; 143032 CL; 94314 CL; 87313 CL;
99333 CL
DR - 0048-U 0184-U 1205-U
DW - 200256
IC - A61K31/137; A61K31/4164; A61K31/436; A61K31/451; A61K9/06; A61K9/08;
A61P1/02; A61P27/02; A61P27/16; A61P29/00
IN - AIKAWA K; ICHIHARA T; NAKAGAMI J; OKUDAIRA I
LNKA- 2002-148589
M2 - [01] F012 F522 G031 G222 M1 M116 M280 M320 M413 M431 M510 M521 M531
M540 M782 M904 M905 P922 P924; RA0JI5-K RA0JI5-M
- [02] G012 G100 H1 H102 H181 H4 H402 H441 H481 H8 M210 M211 M273 M281
M312 M321 M332 M343 M373 M391 M414 M431 M510 M520 M531 M540 M782 M904
M905 M910 P922 P924; R00184-K R00184-M R10162-K R10162-M
- [03] F012 F522 G020 G221 M1 M125 M132 M280 M311 M321 M342 M413 M431
M510 M521 M531 M540 M782 M904 M905 P922 P924; R04370-K R04370-M
R10620-K R10620-M
- [04] G010 G100 H1 H102 H181 H4 H401 H481 H8 M210 M211 M273 M281 M313
M321 M331 M343 M373 M391 M414 M431 M510 M520 M531 M540 M640 M782 M904
M905 M910 P922 P924; R03838-K R03838-M
- [05] G015 G100 H1 H102 H181 H4 H403 H442 H481 H8 M210 M211 M273 M281
M312 M321 M332 M343 M373 M391 M414 M431 M510 M520 M531 M540 M782 M904
M905 M910 P922 P924; R00048-K R00048-M R14840-K R14840-M
- [06] D011 D013 D022 E520 H1 H100 H121 J0 J011 J1 J111 J5 J521 L943
M210 M213 M232 M240 M281 M320 M412 M431 M511 M520 M530 M540 M782 M904
M905 P922 P924; R11928-K R11928-M
- [07] F011 F013 F014 F017 F433 G010 G013 G035 G038 G112 G563 H1 H161 H2
H201 H6 H601 H641 J0 J011 J1 J111 K0 L1 L144 M1 M113 M119 M210 M211
M240 M281 M320 M413 M431 M510 M521 M532 M541 M782 M904 M905 P922 P924;
R14940-K R14940-M R16287-K R16287-M
MC - B06-E05 B07-D05 B07-D09 B10-B03B B14-N02 B14-N03
PA - (TAIS) TAISHO PHARM CO LTD
PN - JP2002161032 A 20020604 DW200256
PR - JP20000279298 20000914
XIC - A61K-031/137; A61K-031/4164; A61K-031/436; A61K-031/451; A61K-009/06;
A61K-009/08; A61P-001/02; A61P-027/02; A61P-027/16; A61P-029/00;
A61K-031/4353; A61P-001/00; A61P-027/00
AB - NOVELTY :
New composition for mucous membrane comprises:
(a) at least one selected from tetrahydrozoline, phenylephrine,
naphazoline, ephedrin and epinephrine; and
(b) at least amlexanox or levocabastine.
- ACTIVITY :
Ophthalmological. No test data provided.
- MECHANISM OF ACTION :

None Given.

06P100

- USE :

The composition is used for alleviating hyperemia of mucous membrane accompanied by rhinocleisis, reddened eye or pharyngeal reddening.

- ADVANTAGE :

The composition can be used as description drugs or treatment agent, which is combined with other anti-allergic agent, anti-histamine, topical anesthetic, anti-choline agent, steroid type anti-inflammatory agent, etc.

- PHARMACEUTICALS :

Preferred composition: The mucous membrane composition is used as nasal drip, eye wash, pharyngeal drug or eye ointment. The amount of (a) in nasal drip or pharyngeal drug is 0.001 - 1 wt.%, preferably 0.005 - 0.5 wt.%, and that in eye wash or eye ointment is 0.0001 - 0.2 wt.%, preferably 0.0005 - 0.1 wt.%. The amount of amlexanox is 0.01 - 1 wt.%, preferably 0.05 - 0.5 wt.%, and that of levocabastine is 0.001 - 0.1 wt.%, preferably 0.005 - 0.05 wt.%. .

- EXAMPLE :

Naphazoline chloride (3 mg), amlexanox (25 mg), dipotassium glycyrrhizinate (300 mg), phosphoric buffer solution (100 mg), benzalkonium chloride (2.5 mg) were dissolved in sterilized water (80 ml), and the whole was adjusted at pH 7.0 by addition of sodium chloride and sodium hydroxide. Sterilized water was added to the obtained mixture to give 100 ml of eye wash.

ICAI- A61K31/137; A61K31/4164; A61K31/436; A61K31/451; A61K9/06; A61K9/08; A61P1/02; A61P27/02; A61P27/16; A61P29/00

ICCI- A61K31/137; A61K31/4164; A61K31/4353; A61K31/451; A61K9/06; A61K9/08; A61P1/00; A61P27/00; A61P29/00

INW - AIKAWA K; ICHIHARA T; MAKAGAMI J; OKUDAIRA I

IW - NEW COMPOSITION MUCOUS MEMBRANE NASAL DRUG OPHTHALMIC WASHING PHARYNGEAL TREAT

IWW - NEW COMPOSITION MUCOUS MEMBRANE NASAL DRUG OPHTHALMIC WASHING PHARYNGEAL TREAT

NC - 1

NFN - 1

OPD - 2000-09-14

PAW - (TAIS) TAISHO PHARM CO LTD

PD - 2002-06-04

RRL - 03505

TI - New composition for mucous membrane, used as nasal drug, ophthalmic wash or pharyngeal drug, for treatment of hyperemia